General Information of Drug (ID: DM1MQ6Z)

Drug Name
SC-102 Drug Info
Synonyms
4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl); SC-102; SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Terminated [1]
Cross-matching ID
PubChem CID
12106168
TTD Drug ID
DM1MQ6Z

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [3]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [3]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [4]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [5]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [3]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [6]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [6]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [6]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [6]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016901)
2 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
5 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
6 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.